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Immunobiologics provide the hope for safe and e¡ec-
tive long-term management of psoriasis, a life-dis-
abling condition. The use of targeted immunotherapies
as pathogenic probes has led to scienti¢c discoveries that
help uncover new information on the pathogenesis of
psoriasis and on the control of cutaneous immunity.
The research described in this paper employs targeted
immunotherapies as pathogenic probes of T1-mediated
immune disorders, using psoriasis as the primary disease
model. This approach has wide applicability to other
immune-mediated in£ammatory isorders. Keywords:
Psoriasis/Immunobiologics/Cytokines/T cell activation. J In-
vestig Dermatol Symp Proc 9:79 ^83, 2004
T
he role of T cells in the pathogenesis of psoriasis was
discovered through serendipity: the clinical use of
targeted immunotherapies as pathogenic probes and,
more recently, the use of SCID mouse models
(Gilhar et al, 1997;Wrone-Smith and Nickolo¡, 1996).
The fact that methotrexate improves psoriatic joint and skin disease
was one of the early clues that cells other than keratinocytes are
pathogenic. Cyclosporine’s dramatic clearing of psoriasis was ¢rst
noted in the mid 1980s, when researchers observed that it inhibits
mRNA transcription for a number of T cell cytokines, strongly
suggesting a pivotal role for T cells in psoriasis pathogenesis (Bos
et al, 1989; Ellis et al, 1991; Gottlieb et al, 1992). It was not conclu-
sive proof, however, because the concentrations of cyclosporine
achieved in the epidermis after oral dosing had direct e¡ects on
keratinocyte proliferation (Khandke et al, 1991). Not until the use
of a targetedTcell toxin, denileukin diftitox, was de¢nitive proof
obtained for the role of T cells in psoriasis pathogenesis.
Denileukin diftitox is a fusion protein of IL-2 and diphtheria
toxin protein fragments which speci¢cally kills activated T cells.
It has no biologic activity in vitro against growth factor^stimu-
lated keratinocytes. As a single agent, denileukin diftitox clears
psoriasis clinically and histologically (Gottlieb et al, 1995), de¢ni-
tively demonstrating that activated Tcells are pivotal in maintain-
ing psoriatic plaques. More recently, SCID mouse models have
con¢rmed pathogenic roles for both CD4þ and CD8þ T cells
and have suggested a potential role for NK cells (Gilhar et al, 1997;
Nickolo¡ et al, 1995).
In general, T cells require two signals in order to be activated.
The ¢rst signal is provided by antigen bound to MHC class I or
II on antigen-presenting cells (APC) (e.g., Langerhans cells) inter-
acting with surface membraneTcell receptors. In the absence of a
second activating signal, however, this interaction fails to activate
the T lymphocyte. The second signal can be supplied by a num-
ber of pairs of surface molecules, including LFA-1-ICAM-1,
CD2-LFA3, and CD80,86-CD28-CTLA-4 (vonNoesel et al,
1988; June et al, 1990; Springer et al, 1987). Recent studies suggest
that LFA^1-ICAM-1 interactions may be more important in an-
choring the immunological synapse between T cells and APC
than in actually providing a second activating signal to T cells
(vanNoesel et al, 1988; Friedrich et al, 2000).
B7.1 (CD80) and B7.2 (CD86) are membrane proteins ex-
pressed primarily on activated APC and on a subset of activated
T cells in psoriatic plaques. The interaction of CD28 with CD80
and CD86 delivers a ‘‘second signal’’ leading to T cell activation,
after which CTLA-4 is upregulated on the T cell surface. In con-
trast to the interaction with CD28, the interaction of CD80 and
CD86 with CTLA-4 leads to deactivation of the T cell and sup-
pression of the immune response.
Soluble CTLA-4-Ig inhibits T cell activation by binding to
CD80 and CD86 on APC, thus inhibiting the binding of T cell-
associated CTLA-4-Ig to surface CD80 and CD86. Forty-three
patients with moderate to severe plaque-type psoriasis received
four intravenous infusions of CTLA-4g. Forty-six percent experi-
enced 50% or more improvement in the Physician’s Global
Assessment (a clinical research tool used to measure disease activity).
Clinical improvement was associated with decreased epidermal
thickness and numbers of epidermal CD3þ Tcells. Additionally,
activated/mature dendritic cells in psoriasis lesions were reversed
by B7 blockade. These results show that the stimulus for ongoing
T cell activation, as well as the ongoing maturation of dendritic
cells, may be sustained by B7^CD28 signaling (Abrams et al,
2000).
IDEC 114 is an anti-CD80 monoclonal antibody that binds
speci¢cally and with high a⁄nity. Signi¢cantly, it blocks the in-
teraction of CD80 with CD28 without a¡ecting the interaction
of CD80 and CTLA-4 in vitro. Twenty-four patients received sin-
gle intravenous infusions of IDEC 114 (Gottlieb et al, 2002b). Evi-
dence of clinical and histologic activity was demonstrated.
A multiple-dose study of IDEC 114 in psoriasis was next con-
ducted.Thirty-¢ve patients received four intravenous infusions of
IDEC 114 ranging from 2.5 to 15.0 mg/kg over a three-week to
six-week period. Clinical improvement was noted in all dosage
groups. Histopathological results, including reduced epidermal
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CD3þ T cell counts, reduced epidermal thickness, and normal-
ization of keratinocyte di¡erentiation, were generally consistent
with clinical outcome. With both CTLA-4-Ig and IDEC 114,
however, many patients did not respond completely, suggesting
that other cellular targets are important in maintaining psoriatic
plaques (Gottlieb, 2002a).
CD45ROþ (‘‘memory e¡ector’’) T cells predominate in psor-
iasis lesions. Alefacept (LFA3TIP) is a 115-kD fusion protein that
consists of the ¢rst extracellular domain of human LFA-3 fused
to the hinge CH2 and CH3 sequences of human IgG1. It binds
CD2 on T cells, leading to inhibition of T cell costimulation
and a reversible reduction of ‘‘memory e¡ector’’ (CD4þ
CD45ROþ, CD8þCD45ROþ ) T cells in peripheral blood
(daSilva et al, 2002). In a small study, clinical response correlated
with depletion of T cells from the epidermis (Springer et al, 1987;
Friedrich et al, 2000; Krueger et al, 2002; Magilavy, 1999).
In a phase II double-blind, placebo-controlled study, 229 mod-
erate to severe psoriasis patients were given 12 weekly intravenous
doses of alefacept (0.025, 0.075, and 0.150 mg/kg versus placebo)
and followed for a 12-week period. At 12 weeks, the mean reduc-
tion in the Psoriasis Area and Severity Index (PASI) was 38%,
53%, and 53% in the 0.025, 0.075, and 0.150 mg/kg groups, re-
spectively, compared with 21% in the placebo group. Alefacept
treatment required approximately three months to show dramatic
clinical response. Of the 29 patients who were clear after 12
weeks, the median time until relapse (i.e., patients were no longer
clear or almost clear) was 236 days. Early reduction in the num-
ber of circulating memoryT cells was associated with clinical re-
sponse. On a population basis, there was a correlation between
reduction in the CD45ROþ (memory) T cell subset early in
treatment and clinical improvement, although early reduction in
memory T cell numbers was neither necessary nor su⁄cient for
clinical response (Ellis et al, 2001).
Phase III trials con¢rmed and extended the observations made
in phase II. Both intramuscular and intravenous formulations
were tested. After one 12-week course of intramuscular alefacept
(15 mg dosed weekly), 33% of patients achieved at least a 75%
reduction in PASI. After two 12-week courses of intramuscular
administration, 43% of patients achieved at least a 75% reduction
in PASI (Langley et al, 2002). Selective reductions in memory ef-
fector (CD45ROþ ) T cells were related to clinical improvement
(Lowe et al, 2002). Alefacept was recently approved by the FDA’s
DermatologyAdvisory Panel as monotherapy for moderate to se-
vere psoriasis.
Efalizumab (anti-CD11a, Raptiva), a non-lymphocyte-deplet-
ing, humanized monoclonal antibody against T cell lymphocyte
LFA-1, has been studied as monotherapy for moderate to severe
plaque psoriasis (Gottlieb et al, 2000; Gordon et al, 2002; Gottlieb
et al, 2002a; Papp et al, 2001). By blocking the interaction between
LFA-1 and ICAM-1, it inhibits both T cell activation and T cell
emigration into skin (reviewed in Gottlieb et al, 2000).
Two phase III clinical trials, enrolling 1095 subjects, were com-
pleted, partially evaluated, and presented at a number of national
and international meetings in 2001. The clinical response to 12
weekly subcutaneous (SC) efalizumab doses was studied. The 11
(primary) endpoint was achievement of 75% or more improve-
ment in PASI. Subjects were randomized to treatment consisting
of an initial conditioning dose of 0.7 mg/kg in week 1 followed
by 11 weekly doses of either 1.0 mg/kg or 2.0 mg/kg of efalizu-
mab or placebo (Gordon et al, 2003).
More subjects (29.2%) treated with efalizumab (1 mg/kg)
achieved at least a 75% PASI improvement in comparison to
those on placebo (3.4%). Combined results from both trials show
that the PASI improvement for both efalizumab groups was im-
proved over that of placebo after only two to four doses
(po0.005).
Immunohistologic studies in phases I and II demonstrated
decreased T cell in¢ltration in plaques and normalization of
keratinocyte di¡erentiation in responding patients. Reductions
in epidermal Tcell number were accompanied by increases in cir-
culating lymphocytes. On the basis of these observations, the re-
searchers hypothesized that efalizumab inhibits T cell emigration
into the skin. CD11a saturation in plaques was necessary but not
su⁄cient for clinical clearance, as de¢ned by the primary end-
point above (Gottlieb et al, 2000; Gottlieb et al, 1999; Papp et al,
2001; Gottlieb et al, 2002a).
The combined data with the T cell^targeting drugs tested to
date suggest that other T cell surface proteins and/or other patho-
genic cell types and molecular pathways are important.
PATHOGENIC CYTOKINES IN PSORIASIS
The in£ammatory response in psoriatic plaques is initiated in part
by activated T cells in the epidermis and dermis. T cells predo-
minate in plaques, releasing a number of in£ammatory cytokines,
including tumor necrosis factor a (TNF-a). TNF-a, interferon g
(IFN-g), interleukin 6 (IL-6), IL-8, IL-12, and other in£amma-
tory cytokines are elevated in psoriatic lesions but not in the nor-
mal skin of psoriatic patients. TNF-a increases the synthesis of
pro-in£ammatory cytokines such as IL-1, IL-6, IL-8, and acti-
vates nuclear transcription factors such as NFkB. In animal models,
transgenic overexpression of TNI results in arthritis, demyelinat-
ing disease, in£ammatory bowel disease, and diabetes (O’Shea
and Lipsky, 2002). Additionally, TNF-a increases hepatocyte
synthesis of acute-phase reactants such as C-reactive protein and
may, in part, account for the constitutional symptoms that severe
psoriasis patients often experience (reviewed in Chaudhari et al,
2001; Gottlieb and Krueger, 2002; Gottlieb et al, 2002c; Gottlieb,
2002).
Psoriasis is an in£ammatory,T cell^mediated disease; however,
what causes activation of these T cells is still unknown. TNF-a
has multiple activities that could increase Langerhans cell activa-
tion of T cells. It induces Langerhans cell maturation, thus allow-
ing these cells to more e⁄ciently present antigen and upregulate
their T cell costimulatory surface molecules. After antigen expo-
sure in the skin, Langerhans cells must exit the skin and travel to
lymph nodes, where presentation of antigen toT cells takes place.
TNF-a is capable of stimulating Langerhans cells to migrate from
the skin to the lymph nodes. Interaction of MHC class I- or II-
bound antigen with the T cell receptor, plus a second activating
signal, causes T cell activation. This leads to T cell expression of
surface membrane proteins, such as cutaneous lymphocyte^asso-
ciated antigen (CLA), allowing them access into the skin. An
additional possible method involves E-cadherin, an adhesion mo-
lecule in the epidermis that enables Langerhans cell binding to
keratinocytes. Expression of E-cadherin potentially retains Lan-
gerhans cells in the epidermis, bound to keratinocytes. TNF-a
decreases E-cadherin expression, which could facilitate the mi-
gration of Langerhans cells from the skin, allowing their travel
to lymph nodes and subsequent T cell activation (Schuler and
Steinman, 1987; Onuma, 1994; Nestle and Nickolo¡, 1995; Mor-
henn, 1997; Kimber et al, 2000; De Boer et al, 1994).
By inducing the synthesis of adhesion molecules on endothe-
lial cells and keratinocytes, TNF-a potentially increases cellular
in¢ltration in skin (Gottlieb et al, 2002a; DeBoer et al, 1994; Gil-
har et al, 1997; Nickolo¡ and Gri⁄ths, 1990; Norris, 1990; Spring-
er, 1990). Leucocyte emigration into skin could also be promoted
by the induction of vascular endothelial growth factor byTNF-a
(Skobe and Detmar, 2000; Xia et al, 2002). Vascular endothelial
growth factor activity increases the number of blood vessels and
may, in part, account for the Auspitz sign that dermatologists ob-
serve in psoriasis patients.
TNF-a increases keratinocyte proliferation in vitro (Gottlieb
et al, 2002c). It has been found to increase type I vasoactive intest-
inal peptide (VIP) receptor mRNA in keratinocytes. Subsequent
binding of VIP to its receptor promotes keratinocyte prolifera-
tion and stimulates synthesis of pro-in£ammatory cytokines such
as IL-6, IL-8, and RANTES (Kakurai et al, 2001). TNF-a in-
creases plasminogen activator inhibitor type 2 (PAI-2), a serine
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proteinase inhibitor, which is thought to protect cells from apop-
tosis (Wang and Jensen, 1998). The prevention of apoptosis by this
or other mechanisms could lead to increased longevity of kerati-
nocytes and consequently to a thickened epidermis.
TNF-a is found at particularly high concentrations in the skin
lesions and plasma of patients with psoriasis (Ettehadi et al, 1994).
In psoriatic arthritis, the concentrations of cytokines secreted by
activated monocytes/macrophages (TNF-a, IL-1, LI-6, and IL-8)
are raised in the synovial £uids and membranes. As well as being
involved in in£ammatory processes,TNF-a is associated, both di-
rectly and indirectly, with bone and cartilage destruction, a fea-
ture of psoriatic arthritis (Mease et al, 2000). Thus, it potentially
contributes to the clinical and histologic phenotype that is char-
acteristic of psoriasis.
INFLIXIMAB
In£iximab is a chimeric IgG1 anti-TNF-a monoclonal antibody
that binds to transmembrane-bound and soluble TNF-a with
high speci¢city, a⁄nity, and avidity (Scallon et al, 1995). Neutra-
lizing transmembrane-bound TNF-a on the cells that synthesize
itfor example, APC, keratinocytes, mast cells, and activated T
cells (Scallon et al, 1995)in£iximab acts like a ‘‘sponge’’ to absorb
soluble circulatingTNF-a. It competes with theTNF receptor for
receptor-bound ligand on target cells, such as lymphocytes, APC,
endothelial cells, and keratinocytes, and has the potential to kill
cells bearing surface TNF-a by both complement-mediated and
antibody-dependent cell-mediated cytotoxicity. In£iximab in-
duces apoptosis of activated T cells in vitro (tenHove et al, 2002).
Although not currently indicated for psoriasis, in£iximab is in-
dicated for moderate to severe Crohn’s disease (for the reduction
of signs and symptoms and closure of enterocutaneous ¢stulas)
and moderate to severe rheumatoid arthritis (for reduction of
signs and symptoms and inhibition of progression of structural
damage) (Chaudhari et al, 2001; Scallon et al, 1995; Maini et al,
1999; Oh et al, 2000; Present et al, 1999;Targan et al, 1997;VanOos-
ten et al, 1996).
In psoriasis, the TNF story started with a 57-year-old female
with recalcitrant, severe psoriasis and Crohn’s disease who was
treated for refractory in£ammatory bowel disease with in£ixi-
mab. The patient had a 15-year history of Crohn’s disease with
dependence on high-dose prednisone (up to 60 mg/day), and a
20-year history of moderate to severe psoriasis treated with topi-
cal corticosteroids. Two weeks after a single infusion of in£ixi-
mab (5 mg/kg), dramatic improvement in the patient’s psoriasis
was demonstrated (Oh et al, 2000). The PASI measured at baseline,
two weeks post-in£iximab infusion, and four weeks post-infusion
were 34.1, 19.9, and 12.1, respectively. By 16 weeks post-infusion,
the patient’s PASI had gradually returned to baseline values of
34.3. The patient received a second dose of in£iximab (5 mg/kg)
16 weeks following the ¢rst dose. As with the ¢rst dose, her
psoriasis and Crohn’s disease followed a similar course of clinical
improvement in follow-up examinations (Oh et al, 2000).
On the basis of this observation, a study of the clinical bene¢t
and safety of in£iximab monotherapy in the treatment of moder-
ate to severe plaque-type psoriasis was executed (Chaudhari et al,
2001). An additional aim of this study was to use in£iximab as a
targeted therapeutic probe to determine the role of TNF-a in
psoriasis pathogenesis. Thirty-three patients with moderate to se-
vere plaque psoriasis were randomized to receive placebo or in-
£iximab 5 or 10 mg/kg infusions at weeks 0, 2, and 6. Patients
were assessed at week 10 for the primary endpoint determination.
Of 11 patients, 9 (81.8%) and 8 (72.7%) had at least 75% improve-
ment in the PASI in the 5- and 10-mg/kg dosing groups, respec-
tively, compared to 2 of 11 (18.2%) in the placebo group (po0.05
for each in£iximab group versus placebo). There were no serious
adverse events, and in£iximab was well tolerated. The fact that
a targeted anti-TNF agent clears psoriasis in 80% of patients
suggests that for most patients TNF-a plays a pivotal role in the
pathogenesis of this condition (Chaudhari et al, 2001).
An open-label extension was next implemented to assess the
ability of in£iximab monotherapy to maintain the clinical bene¢t
achieved following an initial induction regimen. Additionally,
the safety database for in£iximab monotherapy in patients with
moderate to severe plaque psoriasis was expanded. In the open-
label extension, patients received a three-dose induction regimen
of in£iximab 5 or 10 mg/kg at weeks 0, 2, and 6. During weeks 10
through 26, patients were evaluated for loss of response (de¢ned
as loss of at least half of the improvement in the PASI score
achieved at week 10) and were retreated with open-label in£ixi-
mab 5 or 10 mg/kg as needed. Twenty-nine subjects participated.
At week 10, 77% of in£iximab-treated patients achieved at least
75% improvement from baseline in the PASI score. Among the
19 patients who continued in the trial through week 26, 58%
maintained at least 50% improvement and 48% maintained at
least 75% improvement in the PASI score as compared to the
baseline score (Gottlieb et al, 2002e). There were no serious
adverse events, and in£iximab was well tolerated.
The pharmacodynamic response to in£iximab was next inves-
tigated through immunoperoxidase analysis of lesional (weeks 0,
2, 10) and nonlesional (week 0) biopsies for changes in epidermal
CD3þ T cell number, epidermal keratin K16 expression (a mar-
ker of abnormal keratinocyte di¡erentiation), aberrant keratino-
cyte ICAM-1 expression, and epidermal thickness (Gottlieb et al,
2002c). Correlation analyses between histology and clinical e⁄-
cacy measures were performed using the Spearman correlation
test. Rapid and marked decreases in epidermal T cell in¢ltration,
in epidermal thickness, and in keratinocyte adhesion molecule
expression, along with normalization of keratinocyte di¡erentia-
tion, were demonstrated in in£iximab-treated psoriatic plaques.
Decreases in epidermal T cell in¢ltration were highly correlated
with decreases in epidermal thickness. The observed in£iximab-
induced, histologic changes preceded achievement of the clinical
endpoints and showed a high degree of correlation with the clin-
ical scoring systems utilized (Gottlieb et al, 2002c). The combined
clinical and immunohistologic data again demonstrate a pivotal
role for TNF-a in the pathogenesis of psoriasis.
ETANERCEPT
Etanercept is a fusion fragments of protein of twoTNF receptor
p75 extracellular domains with one IgG1 Fc region. It is FDA-
approved for rheumatoid and psoriatic arthritis. Sixty patients
with psoriatic arthritis were enrolled in a double-blind, placebo-
controlled study that compared etanercept (25 mg subcuta-
neously twice a week) with placebo when dosed for 12 weeks
(Mease et al, 2000). The American College of Rheumatology cri-
teria for improvement (ACR 20) (Mease et al, 2000) were used to
assess the clinical response of psoriatic arthritis. In those patients
with 3% or greater body surface area involvement with psoriasis,
PASI and target lesion assessments were done. Forty-seven per-
cent of patients in both the etanercept and placebo groups were
on concurrent methotrexate therapy. Twenty percent in the eta-
nercept group and 40% in the placebo group were on systemic
corticosteroids.
The ACR 20 was achieved by 73% of etanercept patients as
compared with only 13% of placebo patients at 12 weeks. In those
patients evaluable for psoriasis activity, 26% in the etanercept
group achieved 75% or greater improvement in PASI (Frederiks-
son and Pettersson, 1978) as compared with 0% in the placebo
group. Median target lesion improvement was 50% and 0%, re-
spectively, in the two groups. Etanercept was well tolerated, with
injection site reactions being the most common adverse event ob-
served (Mease et al, 2000).
Phase III studies have con¢rmed the clinical results seen in the
phase II studies of psoriatic arthritis (PsA) patients: 205 patients
with PsAwere enrolled; 101 received etanercept and 104 received
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placebo. Patients received 25 mg etanercept or placebo twice
weekly (SC) for 24 weeks. Concomitant therapy with metho-
trexate, oral corticosteroids, and nonsteroidal anti-in£ammatory
drugs was permitted. The primary arthritis endpoint was ACR
20 at 12 weeks. Psoriasis improvement was measured by target
lesion score and, in a subset of patients with psoriasis involvement
X3% (n¼ 66 for etanercept; n¼ 62 for placebo), by the PASI.
Arthritis was signi¢cantly improved with etanercept treatment.
ACR 20 was achieved by 59% of the etanercept group and 15%
of the placebo group at 12 weeks (po0.0001). Signi¢cant im-
provement in arthritis was maintained with continued etanercept
treatment through the end of the study at 24 weeks. AC 70 was
achieved in 11% of the etanercept-treated patients versus 0% of
the placebo-treated patients at 12 weeks. Psoriatic target lesions
were also signi¢cantly improved with etanercept treatment;
median improvement at 24 weeks was 33% in etanercept patients
and 0% in placebo patients (po0.0001). PASI measurements con-
¢rm this result. Etanercept was well tolerated in this patient po-
pulation (Mease et al, 2001) and is FDA approved for psoriatic
arthritis.
The next study examined the e⁄cacy of etanercept as mono-
therapy in patients with psoriasis. In a 24-week multicenter,
blinded, randomized study, patients received etanercept 25 mg
or placebo by SC injection twice weekly. The primary endpoint
was achievement of at least a 75% improvement in PASI (PASI
75) at 12 weeks. One hundred and twelve patients enrolled in
the study. Groups (n¼ 57 for etanercept; n¼ 55 for placebo) were
well-matched for patient age, psoriasis duration, and disease in-
tensity. The percent of patients achieving PASI improvement of
at least 75% at 12 weeks was signi¢cantly higher in the etanercept
group versus the placebo group (30% and 2%, respectively;
po0.0001). E⁄cacy continued to improve with longer treatment,
with 54% of etanercept-treated patients and 5% of placebo-trea-
ted patients reaching PASI 75 at 24 weeks (po0.0001). Statistically
signi¢cant improvements in patient global, physician global, and
target lesion assessments and DLQI (a quality of life question-
naire) con¢rmed the e⁄cacy of etanercept therapy. Etanercept
was well tolerated, with numbers of patients reporting adverse
events similar between groups (70% for etanercept, 67% for pla-
cebo).The rates of adverse events (4.49 per patient-year for etaner-
cept, 5.66 per patient-year for the placebo group) were also
similar. Mild injection site reactions were observed in 9% of the
etanercept-treated patients versus 0% of the placebo-treated pa-
tients. This study provided further evidence that etanercept as
monotherapy for psoriasis is e⁄cacious and well tolerated (Got-
tlieb et al, 2002d).
The accumulated data point to a key role for TNF-a in the
pathogenesis of psoriasis and psoriatic arthritis, rheumatoid ar-
thritis, and Crohn’s disease. Additionally, both in£iximab and eta-
nercept have demonstrated e⁄cacy in ankylosing spondylitis,
suggesting that this disorder, too, is at least partially mediated by
TNF-a. There are case reports and small series of patients with
other immune-mediated in£ammatory diseases treated success-
fully with TNF-targeting immunotherapies (in£iximab). These
include uveitis, Sj˛gren’s syndrome, giant cell arteritis, graft ver-
sus host disease, sarcoidosis, hidradenitis suppurativa, and pyoder-
ma gangrenosum (Chaudhari et al, 2001; Oh et al, 2000;
Braughman and Lower, 2001; Botros et al, 2000; Braun et al,
2002; Cambell and Ghosh, 2001; Couriel et al, 2000; De Clercq,
1987; Fabrizio et al, 2001; Gorman et al, 2002; Martinez et al, 2001;
Schothorst et al, 1991; Smith et al, 2001; Steinfeld et al, 2001; Tan
et al, 2001). Rather than considering these disorders as separate
and localized to nonoverlapping therapeutic areas, perhaps we
should group these diseases by common pathogenesis.
The IL-10 and IL-11 cytokines have been demonstrated in
small clinical trials to shift cytokine expression in psoriatic
plaques of responding patients toward a more normal T1/T2
cytokine expression ratio (Asadullah et al, 1998; Trepicchio et al,
1999). In larger, double-blind, placebo-controlled trials, however,
risk/bene¢t ratios were unsatisfactory. The utility of cytokine
deviation strategies is therefore still an open question. It is possi-
ble that IL-4 may be a more successful candidate to pursue (Tho-
mas, 2001).
CONCLUSION
Although there is more work to be done, immunobiologics pro-
vide the hope for safe and e¡ective long-term management of
life-disabling psoriasis. The use of targeted immunotherapies as
pathogenic probes has led to scienti¢c discoveries that help un-
cover new information on the pathogenesis of psoriasis and on
the control of cutaneous immunity.
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